Abstract
When deciding whether to treat a patient with hypertension, clinicians must balance the benefit of treatment against its adverse effects. In the absence of an interaction, the multiplicative model of risk implies that the absolute benefit of treatment is related to the underlying risk of an adverse outcome. Thus, each additional risk factor multiplies the absolute benefit of treating hypertension. Analyses of data from subgroups in clinical trials of hypertension treatment suggest that this model is usually valid. In contrast, the adverse effects of treatment are usually unrelated to other risk factors. Thus, the cutoff point for treatment differs in different individuals: setting a single treatment threshold and goal for the entire population is not appropriate. Patients who are at high absolute risk because of prior coronary artery disease or other risk factors have a greater potential absolute benefit, and such patients deserve a low threshold and goal, such as a diastolic blood pressure of 90 mm Hg. Conversely, persons at low risk, such as white women without other risk factors, do not require such aggressive management.
References
Aug 16, 1986·British Medical Journal·R G WilcoxJ R Hampton
Nov 1, 1986·Progress in Cardiovascular Diseases·H G LangfordR J Prineas
Jan 1, 1985·The American Journal of Cardiology
Oct 20, 1984·British Medical Journal·A J Silman
Oct 1, 1982·British Journal of Clinical Pharmacology·R Simon
Citations
Jan 1, 1992·Journal of General Internal Medicine·E J Pérez-StableW W Hauck
Oct 1, 1994·Atherosclerosis·K PyöräläD Wood
Apr 12, 2000·The American Journal of Medicine·E J Pérez-StableT J Coates
Aug 8, 2001·Journal of Evaluation in Clinical Practice·J I Robertson
Feb 18, 2005·BMJ : British Medical Journal·James P RafteryLewis D Ritchie
Jul 8, 2010·Indian Journal of Community Medicine : Official Publication of Indian Association of Preventive & Social Medicine·Jacob JohnVinohar Balraj
Apr 1, 1996·The American Journal of the Medical Sciences·C E Lewis
Mar 7, 2014·Thrombosis and Haemostasis·D Aronson
Dec 1, 1994·Patient Education and Counseling·L PetersH P Schaalma
Sep 11, 2003·BMC Cardiovascular Disorders·Kate JollyA J Stevens
Nov 6, 2007·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Ian GrahamUNKNOWN European Atherosclerosis Society (EAS)
Jun 24, 2018·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Sunjae BaeJacqueline M Garonzik Wang
Feb 28, 2002·Circulation·Curt D FurbergStephen Hulley
Jan 12, 1991·BMJ : British Medical Journal·D P Strachan
Apr 1, 1996·Clinical and Experimental Hypertension : CHE·C Borghi, E Ambrosioni
Jun 6, 2019·The Cochrane Database of Systematic Reviews·Vijaya M MusiniJames M Wright
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Vijaya M MusiniJames M Wright
Jan 1, 2014·Molecular Nutrition & Food Research·Iwona RudkowskaMarie-Claude Vohl
May 1, 1989·Hypertension·J A CutlerC D Furberg